LAGEVRIO® (molnupiravir) has provisional approval for the treatment of adults with COVID-19 who do not require initiation of oxygen due to COVID-19 and who are at increased risk for hospitalisation or death. The decision to approve this indication was based on efficacy and safety data from a Phase 3 trial. Continued approval of this indication
This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.